EHNA: Difference between revisions

{{expert-subject|date=March 2010}}

{{drugbox |

| IUPAC_name = 3-(6-aminopurin-9-yl)nonan-2-ol hydrochloride

| ATC_prefix =

| ATC_suffix =

| PubChem = 359137

| DrugBank =

| C = 14 | H = 24 | Cl = 1 | N = 5 | O = 1

| molecular_weight = 313.826 g/mol

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = <!-- A / B / C / D / X -->

| pregnancy_category =

| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 -->

| legal_UK = <!-- GSL / P / POM / CD -->

| legal_US = <!-- OTC / Rx-only -->

| legal_status =

| routes_of_administration =

'''EHNA''' ('''e'''rythro-9-(2-'''h'''ydroxy-3-'''n'''only)'''a'''denine) is a [[phosphodiesterase inhibitor]] that selectively inhibits phosphodiesterase type-2 (PDE2).<ref>{{cite journal | doi = 10.1016/0898-6568(95)00042-N | last1 = Podzuweit | first1 = T | last2 = Nennstiel | first2 = P | last3 = Muller | first3 = A | year = 1995 | title = Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine | url = | journal = Cell Signal | volume = 7 | issue = 7| pages = 733–8 | pmid = 8519602 }}</ref><ref>{{cite journal | last1 = Méry | first1 = PF | last2 = Pavoine | first2 = C | last3 = Pecker | first3 = F | last4 = Fischmeister | first4 = R | year = 1995 | title = Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes | url = | journal = Mol Pharmacol | volume = 48 | issue = 1| pages = 121–130 | pmid = 7623766 }}</ref>

==References==

<references/>

[[Category:Alcohols]]